Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2292MR)

This product GTTS-WQ2292MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2292MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15378MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ4650MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ15789MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ6924MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ4763MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ2689MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ2028MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ12389MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW